Dyadic Logo Current.jpg
Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
January 24, 2023 08:30 ET | Dyadic International, Inc.
JUPITER, Fla., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Pfizer and BioNTech Announce Updated COVID-19 Vaccine Data Supporting Efficacy in Children 6 Months through 4 Years of Age
August 23, 2022 06:45 ET | BioNTech SE
Updated analysis from 34 cases occurring at least seven days following a three-dose regimen showed 73.2% vaccine efficacy among children ages 6 months through 4 yearsThe vaccine efficacy remained...
Pfizer und BioNTech geben Update zur Wirksamkeit ihres COVID-19-Impfstoffs bei Kindern von 6 Monaten bis 4 Jahren
August 23, 2022 06:45 ET | BioNTech SE
Daten einer weiterführenden Analyse mit 34 Fällen, die mindestens sieben Tage nach Verabreichung der primären Impfserie bestehend aus drei Dosen auftraten, zeigen eine Impfstoffwirksamkeit von 73,2 %...
Dr. William Haseltine releases new book on Innate Immunity and Covid-19
March 16, 2022 13:37 ET | ACCESS Health International
New York, March 16, 2022 (GLOBE NEWSWIRE) -- In his latest book, bestselling author William A. Haseltine Ph.D. tells us that understanding our natural immunity to the SARS-CoV-2 virus is critical...
190705_Biontech_Logo_RGB_Dark Green (Preferred)_0.png
Pfizer and BioNTech Submit for U.S. Emergency Use Authorization of an Additional Booster Dose of their COVID-19 Vaccine for Older Adults
March 15, 2022 18:00 ET | BioNTech SE
Submission based on real-world safety and efficacy data from Israel Data showed rates of confirmed infections were 2 times lower and rates of severe illness were 4 times lower among individuals who...
Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age
January 25, 2022 06:45 ET | BioNTech SE
First participants enrolled in clinical trial received Omicron-based vaccine candidate as a two-dose primary series and as a booster dose NEW YORK and MAINZ, GERMANY, JANUARY 25, 2022 — Pfizer Inc....
Pfizer und BioNTech beginnen klinische Studie zu Omikron-basiertem COVID-19-Impfstoff bei Erwachsenen im Alter von 18-55 Jahren
January 25, 2022 06:45 ET | BioNTech SE
Die ersten Teilnehmer erhielten im Rahmen der klinischen Studie den Omikron-basierten Impfstoffkandidaten als Impfserie mit zwei Dosen oder als Auffrischungsimpfung NEW YORK und MAINZ, Deutschland,...
BioNTech and InstaDeep Developed and Successfully Tested Early Warning System to Detect Potential High-Risk SARS-CoV-2 Variants
January 11, 2022 07:00 ET | BioNTech SE
Early Warning System combines Spike protein structural modeling with artificial intelligence (AI) to detect and monitor high-risk SARS-CoV-2 variants, identifying >90% of WHO-designated variants on...
BioNTech und InstaDeep entwickeln und testen erfolgreich ein Frühwarnsystem zur Erkennung potenzieller Hochrisikovarianten von SARS-CoV-2
January 11, 2022 07:00 ET | BioNTech SE
Das Frühwarnsystem kombiniert Strukturmodellierung von Spike-Proteinen mit künstlicher Intelligenz (KI), um Hochrisikovarianten von SARS-CoV-2 zu erkennen und zu überwachen; dabei können...
Dyadic Logo Current.jpg
Dyadic Announces a NIIMBL Coronavirus Grant Under the White House’s American Rescue Plan
December 22, 2021 09:12 ET | Dyadic International, Inc.
JUPITER, Fla., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...